|
1
|
Global Burden of Disease Cancer
Collaboration, ; Fitzmaurice C, Dicker D, Pain A, Hamavid H,
Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, et
al: The global burden of cancer 2013. JAMA Oncol. 1:505–527. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bruix J and Sherman M; American
Association for the Study of Liver Diseases, : Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Roayaie S, Obeidat K, Sposito C, Mariani
L, Bhoori S, Pellegrinelli A, Labow D, Llovet JM, Schwartz M and
Mazzaferro V: Resection of hepatocellular cancer </=2 cm:
Results from two Western centers. Hepatology. 57:1426–1435. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shrager B, Jibara G, Schwartz M and
Roayaie S: Resection of hepatocellular carcinoma without cirrhosis.
Ann Surg. 255:1135–1143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hasegawa K, Kokudo N, Imamura H, Matsuyama
Y, Aoki T, Minagawa M, Sano K, Sugawara Y, Takayama T and Makuuchi
M: Prognostic impact of anatomic resection for hepatocellular
carcinoma. Ann Surg. 242:252–259. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alison MR, Nicholson LJ and Lin WR:
Chronic inflammation and hepatocellular carcinoma. Recent Results
Cancer Res. 185:135–148. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W,
Zhang X, Wang WM, Qiu SJ, Zhou J and Fan J: Systemic
immune-inflammation index predicts prognosis of patients after
curative resection for hepatocellular carcinoma. Clin Cancer Res.
20:6212–6222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang J, Xu L, Luo Y, He F, Zhang Y and
Chen M: The inflammation-based scores to predict prognosis of
patients with hepatocellular carcinoma after hepatectomy. Med
Oncol. 31:8832014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Galdiero MR, Bonavita E, Barajon I,
Garlanda C, Mantovani A and Jaillon S: Tumor associated macrophages
and neutrophils in cancer. Immunobiology. 218:1402–1410. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen H, Xu C, Jin Q and Liu Z: S100
protein family in human cancer. Am J Cancer Res. 4:89–115.
2014.PubMed/NCBI
|
|
11
|
Salama I, Malone PS, Mihaimeed F and Jones
JL: A review of the S100 proteins in cancer. Eur J Surg Oncol.
34:357–364. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Goyette J and Geczy CL:
Inflammation-associated S100 proteins: New mechanisms that regulate
function. Amino Acids. 41:821–842. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gross SR, Sin CG, Barraclough R and
Rudland PS: Joining S100 proteins and migration: for better or for
worse, in sickness and in health. Cell Mol Life Sci. 71:1551–1579.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu R, Duan L, Cui F, Cao J, Xiang Y, Tang
Y and Zhou L: S100A9 promotes human hepatocellular carcinoma cell
growth and invasion through RAGE-mediated ERK1/2 and p38 MAPK
pathways. Exp Cell Res. 334:228–238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu R, Duan L, Ye L, Wang H, Yang X, Zhang
Y, Chen X, Zhang Y, Weng Y, Luo J, et al: S100A9 promotes the
proliferation and invasion of HepG2 hepatocellular carcinoma cells
via the activation of the MAPK signaling pathway. Int J Oncol.
42:1001–1010. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nemeth J, Stein I, Haag D, Riehl A,
Longerich T, Horwitz E, Breuhahn K, Gebhardt C, Schirmacher P, Hahn
M, et al: S100A8 and S100A9 are novel nuclear factor kappa B target
genes during malignant progression of murine and human liver
carcinogenesis. Hepatology. 50:1251–1262. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Funk S, Mark R, Bayo P, Flechtenmacher C,
Grabe N, Angel P, Plinkert PK and Hess J: High S100A8 and S100A12
protein expression is a favorable prognostic factor for survival of
oropharyngeal squamous cell carcinoma. Int J Cancer. 136:2037–2046.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
European Association for the Study of the
Liver, . Electronic address: simpleeasloffice@easloffice.eu;
European Association for the Study of the Liver: EASL Clinical
Practice Guidelines: Management of hepatocellular carcinoma. J
Hepatol. 69:182–236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun HC, Zhang W, Qin LX, Zhang BH, Ye QH,
Wang L, Ren N, Zhuang PY, Zhu XD, Fan J and Tang ZY: Positive serum
hepatitis B e antigen is associated with higher risk of early
recurrence and poorer survival in patients after curative resection
of hepatitis B-related hepatocellular carcinoma. J Hepatol.
47:684–690. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang
W, Xiong YQ, Wu WZ, Wang L, Tang ZY and Sun HC: High expression of
macrophage colony-stimulating factor in peritumoral liver tissue is
associated with poor survival after curative resection of
hepatocellular carcinoma. J Clin Oncol. 26:2707–2716. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Budczies J, Klauschen F, Sinn BV, Győrffy
B, Schmitt WD, Darb-Esfahani S and Denkert C: Cutoff Finder: A
comprehensive and straightforward Web application enabling rapid
biomarker cutoff optimization. PLoS One. 7:e518622012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu GJ, Xu HX, Lu MD, Xie XY, Xu ZF, Zheng
YL and Liang JY: Correlation between enhancement pattern of
hepatocellular carcinoma on real-time contrast-enhanced ultrasound
and tumour cellular differentiation on histopathology. Br J Radiol.
80:321–330. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu
Z, Yin XY and Zheng L: Peritumoral neutrophils link inflammatory
response to disease progression by fostering angiogenesis in
hepatocellular carcinoma. J Hepatol. 54:948–955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Erbel C, Tyka M, Helmes CM, Akhavanpoor M,
Rupp G, Domschke G, Linden F, Wolf A, Doesch A, Lasitschka F, et
al: CXCL4-induced plaque macrophages can be specifically identified
by co-expression of MMP7+S100A8+ in vitro and in vivo. Innate Immu.
21:255–265. 2015. View Article : Google Scholar
|
|
25
|
Hsu K, Chung YM, Endoh Y and Geczy CL:
TLR9 ligands induce S100A8 in macrophages via a STAT3-dependent
pathway which requires IL-10 and PGE2. PLoS One. 9:e1036292014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schlachterman A, Craft WW Jr, Hilgenfeldt
E, Mitra A and Cabrera R: Current and future treatments for
hepatocellular carcinoma. World J Gastroenterol. 21:8478–8491.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fu S, Guo Z, Li S, Kuang M, Hu W, Hua Y,
He X and Peng B: Prognostic value of preoperative serum
gamma-glutamyltranspeptidase in patients with hepatocellular
carcinoma after hepatectomy. Tumour Biol. 37:3433–3440. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma H, Zhang L, Tang B, Wang Y, Chen R,
Zhang B, Chen Y, Ge N, Wang Y, Gan Y, et al:
γ-Glutamyltranspeptidase is a prognostic marker of survival and
recurrence in radiofrequency-ablation treatment of hepatocellular
carcinoma. Ann Surg Oncol. 21:3084–3089. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang JB, Chen Y, Zhang B, Xie X, Zhang L,
Ge N, Ren Z and Ye SL: Prognostic significance of serum
gamma-glutamyl transferase in patients with intermediate
hepatocellular carcinoma treated with transcatheter arterial
chemoembolization. Eur J Gastroenterol Hepatol. 23:787–793. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Arai K, Yamada T and Nozawa R:
Immunohistochemical investigation of migration inhibitory
factor-related protein (MRP)-14 expression in hepatocellular
carcinoma. Med Oncol. 17:183–188. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pang MF, Georgoudaki AM, Lambut L,
Johansson J, Tabor V, Hagikura K, Jin Y, Jansson M, Alexander JS,
Nelson CM, et al: TGF-β1-induced EMT promotes targeted migration of
breast cancer cells through the lymphatic system by the activation
of CCR7/CCL21-mediated chemotaxis. Oncogene. 35:748–760. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ricciardi M, Zanotto M, Malpeli G, Bassi
G, Perbellini O, Chilosi M, Bifari F and Krampera M:
Epithelial-to-mesenchymal transition (EMT) induced by inflammatory
priming elicits mesenchymal stromal cell-like immune-modulatory
properties in cancer cells. Br J Cancer. 112:1067–1075. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
van Zijl F, Zulehner G, Petz M, Schneller
D, Kornauth C, Hau M, Machat G, Grubinger M, Huber H and Mikulits
W: Epithelial-mesenchymal transition in hepatocellular carcinoma.
Future Oncol. 5:1169–1179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zheng X, Gai X, Wu Z, Liu Q and Yao Y:
Metastasin leads to poor prognosis of hepatocellular carcinoma
through partly inducing EMT. Oncol Rep. 29:1811–1818. 2013.
View Article : Google Scholar : PubMed/NCBI
|
